Interaction Checker

Rifaximine : interactions médicamenteuses

Rifaximine (Xifaxan), antibiotique, présente 59 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 0 de niveau majeur, 31 de niveau modéré, 28 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions modérées (31)

  • Abrocitinibinhibiteur de JAKModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • AmiodaroneantiarythmiqueModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • CiclosporineimmunosuppresseurModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Clarithromycineantibiotique macrolideModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Darunavir et cobicistatantirétroviralModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Diltiazeminhibiteur calciqueModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • DronédaroneantiarythmiqueModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • ÉtravirineantirétroviralModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Flibansérinedépresseur du SNCModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Itraconazoleantifongique azoléModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Ivacaftorinhibiteur du CYP3A4Modérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Kétoconazoleantifongique azoléModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Lapatinibinhibiteur de la glycoprotéine PModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Lédipasvir et sofosbuvirantiviralModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Lopinavir et ritonavirantirétroviralModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Mirabégronagoniste bêta-adrénergiqueModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Mitapivatinducteur du CYP3A4Modérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Nilotinibmédicament allongeant l'intervalle QTModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Nirmatrelvir et ritonavirantiviralModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Posaconazoleantifongique azoléModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • PropafénoneantiarythmiqueModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • QuinidineantiarythmiqueModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Ranolazinemédicament allongeant l'intervalle QTModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • RitonavirantirétroviralModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Sofosbuvir et velpatasvirantiviralModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Suvorexantsédatif-hypnotiqueModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Ticagrélorantiagrégant plaquettaireModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • Vérapamilinhibiteur calciqueModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

  • WarfarineanticoagulantModérée

    Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. (notice Rifaximine, Interactions médicamenteuses)

  • ZonisamideanticonvulsivantModérée

    • Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed. (notice Rifaximine, Mises en garde et précautions)

Mentions mineures (28)

  • Aprépitantinhibiteur du CYP3A4Mineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Bosentaninducteur du CYP3A4Mineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • CarbamazépineanticonvulsivantMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • CénobamateanticonvulsivantMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • ClobazambenzodiazépineMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • GriséofulvineantifongiqueMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Lorlatinibinducteur du CYP3A4Mineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Mitotaneinducteur du CYP3A4Mineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Modafinilstimulant du SNCMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Nafcillineantibiotique de la famille des pénicillinesMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • NévirapineantirétroviralMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • OxcarbazépineanticonvulsivantMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • PhénobarbitalbarbituriqueMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Phentermine et topiramatestimulant du SNCMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • PrimidoneanticonvulsivantMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • RifabutineantibiotiqueMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • RifampicineantibiotiqueMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • RifapentineantibiotiqueMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • Suzétrigineinducteur du CYP3A4Mineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

  • TopiramateanticonvulsivantMineure

    CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (notice Rifaximine, Interactions médicamenteuses)

Vérifiez Rifaximine avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.